EGFR and lung carcinoma: There are targeted therapies available for patients with advanced lung adenocarcinoma, and the most recent National Comprehensive Cancer Network (NCCN) lung cancer recommendations advocate for further identification of relevant drug targets, including mutant EGFR (19DEL, L858R).